Clinical Adoption & Readiness

ISSCR ensures that stem cell–based therapies are translated into clinical practice safely, effectively, and appropriately. Through guidance, education, and stakeholder alignment, we support evidence-based use and protect patients from unproven or premature interventions.
KEY AREAS
Clinical Guidance & Best Practices
Defining appropriate use and standards for clinical application.
Consensus on Emerging Therapies
Providing clarity on evolving clinical approaches and technologies.
Patient & Public Trust
Delivering trusted, evidence-based information to support informed decisions.
System Readiness & Alignment
Supporting integration across clinicians, regulators, and health systems.

News

ISSCR News

Take Action to Preserve Merit-Based Science and International Collaborations

The White House Office of Management and Budget (OMB) has proposed a new rule titled “Regulation for Federal Financial Assistance” that will significantly reshape how the U.S. government funds and manages scientific research, including international collaborations, through the National Institutes of Health (NIH) and other agencies. All ISSCR members, regardless of whether you are U.S.-based or not, are eligible to provide comment on the proposed policy.

Though the rule is extensive and applies to all federal grantmaking, there are several areas where input from our community is critical.

The ISSCR Joins Coalition Letter in Support of the National Institutes of Health (NIH)

The ISSCR joined more than 110 organizations in the cell and gene therapy sector to urge congressional appropriators to provide at least $51.303 billion for the National Institutes of Health (NIH) for fiscal year 2027. This funding level would represent a robust investment in important biomedical research and a meaningful increase over enacted fiscal year 2026 levels. NIH funding remains foundational to the continued advancement of stem cell research. Strong support for NIH will ensure the continued translation of stem cell research into the clinic and to the lives of patients. In addition to the funding request, the letter urges the timely distribution of NIH funding to ensure biomedical research can continue without disruption.

The ISSCR Urges Continued NIH Investment in Human Embryonic Stem Cell Research to Sustain Scientific Progress and Therapeutic Innovation

The International Society for Stem Cell Research (ISSCR) has submitted a formal response to a Request for Information (RFI) issued by the National Institutes of Health (NIH) regarding its pause on new submissions to the NIH Human Embryonic Stem Cell (hESC) Registry and considerations to reduce reliance on hESCs in federally supported research.

‍Representing nearly 5,000 scientists, clinicians, ethicists, and industry leaders worldwide, the ISSCR underscores that continued investment in hESC research is essential to sustaining scientific progress and advancing life-saving therapies.